Company: IMCR
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001671927-25-000014
Chunk: 18

Company: Immunocore Holdings plc
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 18
---
 $1,149,643 $(744,674)$(36,261)$368,843 Net loss— — — — — (24,436)— (24,436)Other comprehensive income— — — — — — 897 897 Exercise of share options280,436 1 — — 5,212 — — 5,213 Share-based compensation expense— — — — 9,017 — — 9,017 As of March 31, 202450,006,085$135 5,793,501$1 $1,163,872 $(769,110)$(35,364)$359,534 Net loss—— —— — (11,616)— (11,616)Other comprehensive income—— —— — — 944 944 Exercise of share options11,521— —— 297 — — 297 Share-based compensation expense—— —— 9,978 — — 9,978 As of June 30, 202450,017,606$135 5,793,501$1 $1,174,147 $(780,726)$(34,420)$359,137 

The accompanying notes form an integral part of these condensed consolidated financial statements.

5

Table of Contents

Immunocore Holdings plc

Condensed Consolidated Statements of Cash Flows

(Unaudited) (In thousands)

Six Months Ended June 30,20252024Cash flows from operating activities Net loss$(5,277)$(36,052)Adjustments for:Share-based compensation expense19,522 18,964 Depreciation1,634 2,003 Unrealized foreign exchange (gains) losses, net(607)1,404 Unrealized gains on marketable securities(10,162)(4,613)Non-cash lease expense1,114 864 Other1,049 951 Changes in assets and liabilities:Increase in accounts receivable(3,341)(8,861)Decrease (increase) in prepayments and other current assets365 (4,058)(Decrease) increase in accounts payable(3,587)2,164 Increase in accrued expenses22,787 46,031 Decrease in deferred revenue(97)— Decrease in operating lease